The CVS stock forecast 2025 points toward improved ROI from in‑store clinic services, as patient convenience remains a strong competitive advantage in the healthcare retail market. CVS' focus on improving margins could ease competition for other health insurers in 2025, Stephens analyst Scott Fidel said, adding that it should particularly benefit UnitedHealth, while also reducing pressure on Humana. $CVS insiders have traded $CVS stock on the open market 8 times in the past 6 months. Of those trades, 1 have been purchases and 7 have been sales. Market reports indicate CVS may benefit from demographic trends in 2025, with aging populations driving pharmacy demand. The CVS stock forecast 2025 thus leans toward mid‑single‑digit price appreciation.